These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 8844631)

  • 21. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial.
    Cravioto MD; Durand-Carbajal M; Jiménez-Santana L; Lara-Reyes P; Seuc AH; Sánchez-Guerrero J
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1654-63. PubMed ID: 22127965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group.
    Good WR; John VA; Ramirez M; Higgins JE
    Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
    Wassertheil-Smoller S; Hendrix SL; Limacher M; Heiss G; Kooperberg C; Baird A; Kotchen T; Curb JD; Black H; Rossouw JE; Aragaki A; Safford M; Stein E; Laowattana S; Mysiw WJ;
    JAMA; 2003 May; 289(20):2673-84. PubMed ID: 12771114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
    Schram JH; Boerrigter PJ; The TY
    Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
    Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM
    J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
    Strickler R; Stovall DW; Merritt D; Shen W; Wong M; Silfen SL
    Obstet Gynecol; 2000 Sep; 96(3):359-65. PubMed ID: 10960626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease.
    Hall G; Pripp U; Schenck-Gustafsson K; Landgren BM
    Maturitas; 1998 Jan; 28(3):235-42. PubMed ID: 9571599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.
    Thromb Haemost; 1996 Mar; 75(3):476-80. PubMed ID: 8701411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
    Utian WH; Shoupe D; Bachmann G; Pinkerton JV; Pickar JH
    Fertil Steril; 2001 Jun; 75(6):1065-79. PubMed ID: 11384629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.
    Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine effects of different estradiol-progestin regimens in postmenopausal women.
    Stomati M; Bersi C; Rubino S; Palumbo M; Comitini G; Genazzani AD; Santuz M; Petraglia F; Genazzani AR
    Maturitas; 1997 Dec; 28(2):127-35. PubMed ID: 9522320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
    Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
    Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
    Cauley JA; Robbins J; Chen Z; Cummings SR; Jackson RD; LaCroix AZ; LeBoff M; Lewis CE; McGowan J; Neuner J; Pettinger M; Stefanick ML; Wactawski-Wende J; Watts NB;
    JAMA; 2003 Oct; 290(13):1729-38. PubMed ID: 14519707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
    Lahdenperä S; Puolakka J; Pyörälä T; Luotola H; Taskinen MR
    Atherosclerosis; 1996 May; 122(2):153-62. PubMed ID: 8769679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone replacement therapy and lipid-lipoprotein concentrations.
    Gökmen O; Yapar Eyi EG
    Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):31-41. PubMed ID: 10428319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.